Entering text into the input field will update the search result below

Biogen up as Guggenheim upgrades citing full approval for Leqembi

May 01, 2023 8:47 AM ETBiogen Inc. (BIIB) StockESALF, SAGE, ESAIYBy: Dulan Lokuwithana, SA News Editor
manhattan office building

franckreporter

After three straight sessions of gains, Biogen (NASDAQ:BIIB) shares continued to rise in the pre-market Monday as Guggenheim upgraded the biotech citing full FDA approval for its Alzheimer's therapy Leqembi developed with Eisai (OTCPK:ESALF)(OTCPK:ESAIY).

Last week, Centers for Medicare and Medicaid

Recommended For You

More Trending News

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIIB--
Biogen Inc.